Rotigotin

Rotigotin transdermalni flaster

(IUPAC) ime
(S)-6-[propil(2-tiofen-2-iletil)amino]-5,6,7,8- tetrahidronaftalen-1-ol
Klinički podaci
AHFS/Drugs.com	Mikromedeks, detaljne potrošačke informacije
MedlinePlus	a607059
Identifikatori
CAS broj	92206-54-7
ATC kod	N04BC09
PubChem[1][2]	57537
DrugBank	DB05271
ChemSpider[3]	51867
UNII	87T4T8BO2E Y
ChEMBL[4]	CHEMBL1303 Y
Hemijski podaci
Formula	C19H25NOS
Mol. masa	315,474 g/mol
SMILES	eMolekuli & PubHem
InChI InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3 Y Key: KFQYTPMOWPVWEJ-UHFFFAOYSA-N Y
Farmakokinetički podaci
Bioraspoloživost	37% (transdermalno)
Vezivanje za proteine plazme	92%
Metabolizam	Hepatički (CYP-posredovano)
Poluvreme eliminacije	5–7 sati
Izlučivanje	Urin (71%), Fekalije (23%)
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	℞ Prescription only
Način primene	Transdermalni flaster

Rotigotin (Neupro) je neergolinski dopaminski agonist koji se koristi za lečenje Parkinsonove bolesti i sindroma nemirnih nogu (RLS) u Evropi i SAD-u.^[5][6] On se formuliše kao jednodnevni transdermalni flaster koji omogućava spor i konstantan unos leka tokom 24 časovnog perioda.^[5][5]

Poput drugih dopaminskih agonista, za rotigotin je pokazano da poseduje antidepresivne efekte i da može da bude koristan u lečenju depresije.^[7]

1. ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
2. ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
3. ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
4. ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
5. ↑ ^{5,0 5,1 5,2} Chen JJ, Swope DM, Dashtipour K, Lyons KE (December 2009). „Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease”. Pharmacotherapy 29 (12): 1452–67. DOI:10.1592/phco.29.12.1452. PMID 19947805. 
6. ↑ Davies S (September 2009). „Rotigotine for restless legs syndrome”. Drugs of Today (Barcelona, Spain : 1998) 45 (9): 663–8. DOI:10.1358/dot.2009.45.9.1399952. PMID 19956807. 
7. ↑ Bertaina-Anglade V, La Rochelle CD, Scheller DK (October 2006). „Antidepressant properties of rotigotine in experimental models of depression”. European Journal of Pharmacology 548 (1-3): 106–14. DOI:10.1016/j.ejphar.2006.07.022. PMID 16959244.